MAPT and Alzheimer disease: Another reliable biomarker, the pRNFL-G, effectively differentiates between FTD from mild AD and HCs in [78], moderate AD from HCs in [78], MCI from HCs in [53, 78], as well as detecting pathological Aβ42/tau in cognitively healthy individuals [75].